Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Glaxo Wellcome |
---|---|
Information provided by: | NIH AIDS Clinical Trials Information Service |
ClinicalTrials.gov Identifier: | NCT00002286 |
To evaluate the feasibility of Retrovir (AZT) in the treatment of psoriasis in HIV antibody positive patients. Retrovir has been shown to be effective in the treatment of AIDS. In addition, the administration of AZT appears to have induced a remission of psoriasis in one case study. In light of AZT's antiviral activity and potential effectiveness as an agent for the treatment of psoriasis, this would be the most likely treatment for HIV positive, psoriatic patients whose disease progresses quickly.
Condition | Intervention |
---|---|
HIV Infections Psoriasis |
Drug: Zidovudine |
Study Type: | Interventional |
Study Design: | Treatment, Dose Comparison |
Official Title: | Retrovir Capsules in the Treatment of Psoriasis in HIV Antibody Positive Patients: A Pilot Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Study participants must have biopsy-proven psoriasis with 3 distinct psoriatic lesions. (Biopsy-proven Reiter's syndrome patients with 3 distinct cutaneous lesions may be included.) Documented HIV antibody (by federally licensed ELISA test) positive patients.
Prior Medication:
Allowed:
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
Concurrent Medication:
Excluded:
- Topical steroid, anthralin, or tar preparations. Etretinate, methotrexate, or psoralen ultraviolet A (PUVA) therapy. Psoriatic treatment such as systemic agents or topical steroids (emollients used distal to the control lesions and antipruritic shampoos are admissible).
Patients with the following are excluded:
Prior Medication:
Excluded:
Study ID Numbers: | 014F, 16 |
Study First Received: | November 2, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00002286 |
Health Authority: | United States: Food and Drug Administration |
Pilot Projects Psoriasis Acquired Immunodeficiency Syndrome Zidovudine |
Sexually Transmitted Diseases, Viral HIV Antibodies Skin Diseases Acquired Immunodeficiency Syndrome Zidovudine Immunologic Deficiency Syndromes Virus Diseases Antibodies |
HIV Seropositivity HIV Infections Psoriasis Sexually Transmitted Diseases Retroviridae Infections Skin Diseases, Papulosquamous Immunoglobulins |
Antimetabolites Anti-Infective Agents RNA Virus Infections Anti-HIV Agents Slow Virus Diseases Immune System Diseases Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors |
Infection Antiviral Agents Pharmacologic Actions Reverse Transcriptase Inhibitors Anti-Retroviral Agents Therapeutic Uses Lentivirus Infections Nucleic Acid Synthesis Inhibitors |